This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

AstraZeneca Announces New Safety Data For Naloxegol In Patients With Opioid-Induced Constipation

AstraZeneca (NYSE: AZN) today announced the results of a Phase III long-term safety and tolerability study of the once-daily 25mg dose of naloxegol, in patients with non-cancer pain and opioid-induced constipation (OIC). Naloxegol is an investigational peripherally-acting mu-opioid receptor antagonist (PAMORA), which has been studied in OIC in adult patients with chronic non-cancer pain, a common condition caused by prescription opioid pain medicines. Data were presented at the American College of Gastroenterology (ACG) 2013 Annual Scientific Meeting in San Diego, California.

The Phase III study, KODIAC-08 (n=844), was a 52-week, long-term safety trial of naloxegol (n=534) vs. usual care (n=270) in patients with non-cancer related pain and OIC. Usual care was defined as the investigator’s choice of an existing laxative treatment regimen for OIC.

“The data from the long-term safety study further support the safety and tolerability of naloxegol, a PAMORA which could help address an unmet need for millions of patients with OIC.” said Kathleen Cantagallo, Clinical VP, naloxegol, AstraZeneca.

Data from KODIAC-08 reinforces the safety and tolerability findings from previous Phase III studies, KODIAC-04 and -05. Data from KODIAC-08 included:

  • Most naloxegol-emergent gastrointestinal adverse events (AEs) occurred early in treatment and were transient with 9 patients (1.6%) discontinuing naloxegol due to abdominal pain;
  • Most common treatment-emergent AEs occurring more often with naloxegol vs. usual care were abdominal pain (17.8% vs. 3.3%), diarrhoea (12.9% vs. 5.9%), nausea (9.4% vs. 4.1%), headache (9.0% vs. 4.8%), and flatulence (6.9% vs. 1.1%);
  • There were no imbalances seen in the independently adjudicated cardiovascular events between the two groups - 2 patients in each arm of the study had major adverse cardiovascular events (MACE) and these events were not attributed to study drug;
  • There were two opioid withdrawal AEs reported in patients taking naloxegol (both were attributed to decreases or discontinuation of opioid medication and both were deemed unrelated to treatment with naloxegol);
  • Pain scores and opioid doses were comparable between treatment groups and were stable throughout the study;
  • No bowel perforations occurred in either group of the study.

In addition to the new safety data for naloxegol presented at the 2013 American College of Gastroenterology (ACG) Meeting, there are two additional data presentations for naloxegol at the meeting:

  • Tuesday, October 15, Plenary Session 2: Endoscopy/Functional Bowel Disorders; Chey et. al. “ Naloxegol Symptom Responder Rates in Patients With Opioid-Induced Constipation: Results From 2 Prospective Randomized Controlled Trials”
  • Tuesday, October 15, Poster Session: “Chey et. al., “ Efficacy of Naloxegol in a Subpopulation of Patients With Opioid-Induced Constipation and an Inadequate Baseline Response to Laxatives: Results From 2 Prospective, Randomized, Controlled Trials

NOTES TO EDITORS

About Naloxegol

Naloxegol is an investigational peripherally-acting mu-opioid receptor antagonist (PAMORA), which has been specifically designed for the treatment of opioid-induced constipation (OIC), a condition caused by prescription opioid pain medicines. Naloxegol is a once-daily tablet designed to block the binding of opioids to the opioid receptors in the gastrointestinal (GI) tract without impacting the opioid receptors in the brain.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,098.45 +18.88 0.11%
S&P 500 2,003.37 +6.63 0.33%
NASDAQ 4,580.2710 +22.5760 0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs